* Cardiff Oncology Inc reported a quarterly adjusted loss of 22 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of four analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -27 cents to -23 cents per share.
* Revenue rose 147% to $205.00 thousand from a year ago; analysts expected $55.00 thousand.
* Cardiff Oncology Inc's reported EPS for the quarter was a loss of 22 cents.
* The company reported a quarterly loss of $10.02 million.
* Cardiff Oncology Inc shares had fallen by 20.8% this quarter and gained 185.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 13.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Cardiff Oncology Inc is $10.50 This summary was machine generated from LSEG data May 2 at 09:42 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.25 -0.22 Beat
Dec. 31 2023 -0.28 -0.21 Beat
Sep. 30 2023 -0.28 -0.22 Beat
Jun. 30 2023 -0.26 -0.25 Beat
Comments